Assess whether biosimilarity is analytically justified (a2ecf6)

Situation

In a mid-size sponsor after a complete response letter, disproportionate reporting signal workbook is the evidence after a competitor label that just got a narrower indication. 505(b)(2) development lead has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy close using disproportionate reporting signal workbook.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a competitor label that just got a narrower indication.

Hypotheses to test

• Disproportionate reporting signal workbook reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• Disproportionate reporting signal workbook is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in disproportionate reporting signal workbook for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.
• Disproportionate reporting signal workbook is missing the fact 505(b)(2) development lead needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether disproportionate reporting signal workbook supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a competitor label that just got a narrower indication and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.